For the above-mentioned reasons, the current discussion on differential gain and risks between ranibizumab and bevacizumab must be confined to data from CATT and IVAN, the only studies available with I/A quality of evidence. Since there are no statistical significant differences between comparable treatment groups of bevacizumab and ranibizumab in terms of efficacy, the focus is on safety only.
The known vascular endothelial growth factor related adverse effects, such as myocardial infarction and stroke, do not differ between the drugs.
The only statistically significant differences between ranibizumab and bevacizumab in the CATT study are gastrointestinal disorders: "e.g., haemorrhage, hernia, nausea, and vomiting." Yet according to the label of Avastin® and to a meta-analysis [3] , only tumourassociated gastrointestinal perforations and fistulas are specific to bevacizumab. Gastrointestinal perforations and fistulas were reported neither in the CATT study nor in the IVAN study. Kaiser and colleagues point to "the overall significantly higher risk of serious systemic adverse events with bevacizumab versus ranibizumab" in the CATT study. However, this part of the CATT data must be considered as inconclusive, since "when all known vascular endothelial growth factor-related serious adverse events are excluded, most of the imbalance remains, leaving it uncertain whether this difference was the result of chance, imbalances at baseline not captured in multivariate modelling, or truly higher risk" [1] .
CATT study and the IVAN study [3] . Finally, if the study population of CATT and IVAN does not reveal differential risks in serious adverse effects (similar to the Anchor and Marina studies with respect to thromboembolic risks), this qualifies the postulated gastrointestinal risks as rare and of overall low relevance.
In contradiction to Kaiser and colleagues, the evidence from the CATT and IVAN studies signals similar efficacy and safety profiles between ranibizumab and bevacizumab. On these grounds, it is justified to include cost considerations in our prescription behaviour.
